Risk of Major Congenital Malformations and Exposure to Antiseizure Medication Monotherapy

Authors:
  • ECEurap Collaborators
    Eurap Collaborators
Top Cited Papers
Open Access
Publisher website
Google Scholar
Abstract
The possibility of prenatal exposure to antiseizure medications (ASMs) leading to increased risk of congenital anomalies has been a concern for more than 5 decades.1 Because most women with epilepsy (WWE) need to continue ASM treatment during pregnancy,2 identifying the safest treatment options for these women is essential. This information could also be applicable to women of childbearing potential who are taking ASMs for nonepilepsy conditions such as psychiatric disorders, migraine, and neuropathic pain.3,4 The assessment of pregnancy outcomes after exposure to different ASMs faces many challenges. Ethical constraints preclude the conduction of randomized studies, leaving observational studies as the sole option. Enrollment of large cohorts is also required to handle the influence of confounding variables.

This publication has 41 references indexed in Scilit: